Cargando…

Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome

BACKGROUND: Recently, metabolic syndrome (MS) has gained attention in human metabolic medicine given its associations with development of type 2 diabetes mellitus and cardiovascular disease. Canine obesity is associated with the development of insulin resistance, dyslipidaemia, and mild hypertension...

Descripción completa

Detalles Bibliográficos
Autores principales: Tvarijonaviciute, Asta, Ceron, Jose J, Holden, Shelley L, Cuthbertson, Daniel J, Biourge, Vincent, Morris, Penelope J, German, Alexander J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514388/
https://www.ncbi.nlm.nih.gov/pubmed/22929809
http://dx.doi.org/10.1186/1746-6148-8-147
_version_ 1782252031505858560
author Tvarijonaviciute, Asta
Ceron, Jose J
Holden, Shelley L
Cuthbertson, Daniel J
Biourge, Vincent
Morris, Penelope J
German, Alexander J
author_facet Tvarijonaviciute, Asta
Ceron, Jose J
Holden, Shelley L
Cuthbertson, Daniel J
Biourge, Vincent
Morris, Penelope J
German, Alexander J
author_sort Tvarijonaviciute, Asta
collection PubMed
description BACKGROUND: Recently, metabolic syndrome (MS) has gained attention in human metabolic medicine given its associations with development of type 2 diabetes mellitus and cardiovascular disease. Canine obesity is associated with the development of insulin resistance, dyslipidaemia, and mild hypertension, but the authors are not aware of any existing studies examining the existence or prevalence of MS in obese dogs. Thirty-five obese dogs were assessed before and after weight loss (median percentage loss 29%, range 10-44%). The diagnostic criteria of the International Diabetes Federation were modified in order to define canine obesity-related metabolic dysfunction (ORMD), which included a measure of adiposity (using a 9-point body condition score [BCS]), systolic blood pressure, fasting plasma cholesterol, plasma triglyceride, and fasting plasma glucose. By way of comparison, total body fat mass was measured by dual-energy X-ray absorptiometry, whilst total adiponectin, fasting insulin, and high-sensitivity C-reactive protein (hsCRP) were measured using validated assays. RESULTS: Systolic blood pressure (P = 0.008), cholesterol (P = 0.003), triglyceride (P = 0.018), and fasting insulin (P < 0.001) all decreased after weight loss, whilst plasma total adiponectin increased (P = 0.001). However, hsCRP did not change with weight loss. Prior to weight loss, 7 dogs were defined as having ORMD, and there was no difference in total fat mass between these dogs and those who did not meet the criteria for ORMD. However, plasma adiponectin concentration was less (P = 0.031), and plasma insulin concentration was greater (P = 0.030) in ORMD dogs. CONCLUSIONS: In this study, approximately 20% of obese dogs suffer from ORMD, and this is characterized by hypoadiponectinaemia and hyperinsulinaemia. These studies can form the basis of further investigations to determine path genetic mechanisms and the health significance for dogs, in terms of disease associations and outcomes of weight loss.
format Online
Article
Text
id pubmed-3514388
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35143882012-12-05 Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome Tvarijonaviciute, Asta Ceron, Jose J Holden, Shelley L Cuthbertson, Daniel J Biourge, Vincent Morris, Penelope J German, Alexander J BMC Vet Res Research Article BACKGROUND: Recently, metabolic syndrome (MS) has gained attention in human metabolic medicine given its associations with development of type 2 diabetes mellitus and cardiovascular disease. Canine obesity is associated with the development of insulin resistance, dyslipidaemia, and mild hypertension, but the authors are not aware of any existing studies examining the existence or prevalence of MS in obese dogs. Thirty-five obese dogs were assessed before and after weight loss (median percentage loss 29%, range 10-44%). The diagnostic criteria of the International Diabetes Federation were modified in order to define canine obesity-related metabolic dysfunction (ORMD), which included a measure of adiposity (using a 9-point body condition score [BCS]), systolic blood pressure, fasting plasma cholesterol, plasma triglyceride, and fasting plasma glucose. By way of comparison, total body fat mass was measured by dual-energy X-ray absorptiometry, whilst total adiponectin, fasting insulin, and high-sensitivity C-reactive protein (hsCRP) were measured using validated assays. RESULTS: Systolic blood pressure (P = 0.008), cholesterol (P = 0.003), triglyceride (P = 0.018), and fasting insulin (P < 0.001) all decreased after weight loss, whilst plasma total adiponectin increased (P = 0.001). However, hsCRP did not change with weight loss. Prior to weight loss, 7 dogs were defined as having ORMD, and there was no difference in total fat mass between these dogs and those who did not meet the criteria for ORMD. However, plasma adiponectin concentration was less (P = 0.031), and plasma insulin concentration was greater (P = 0.030) in ORMD dogs. CONCLUSIONS: In this study, approximately 20% of obese dogs suffer from ORMD, and this is characterized by hypoadiponectinaemia and hyperinsulinaemia. These studies can form the basis of further investigations to determine path genetic mechanisms and the health significance for dogs, in terms of disease associations and outcomes of weight loss. BioMed Central 2012-08-28 /pmc/articles/PMC3514388/ /pubmed/22929809 http://dx.doi.org/10.1186/1746-6148-8-147 Text en Copyright ©2012 Tvarijonaviciute et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tvarijonaviciute, Asta
Ceron, Jose J
Holden, Shelley L
Cuthbertson, Daniel J
Biourge, Vincent
Morris, Penelope J
German, Alexander J
Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome
title Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome
title_full Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome
title_fullStr Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome
title_full_unstemmed Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome
title_short Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome
title_sort obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514388/
https://www.ncbi.nlm.nih.gov/pubmed/22929809
http://dx.doi.org/10.1186/1746-6148-8-147
work_keys_str_mv AT tvarijonaviciuteasta obesityrelatedmetabolicdysfunctionindogsacomparisonwithhumanmetabolicsyndrome
AT ceronjosej obesityrelatedmetabolicdysfunctionindogsacomparisonwithhumanmetabolicsyndrome
AT holdenshelleyl obesityrelatedmetabolicdysfunctionindogsacomparisonwithhumanmetabolicsyndrome
AT cuthbertsondanielj obesityrelatedmetabolicdysfunctionindogsacomparisonwithhumanmetabolicsyndrome
AT biourgevincent obesityrelatedmetabolicdysfunctionindogsacomparisonwithhumanmetabolicsyndrome
AT morrispenelopej obesityrelatedmetabolicdysfunctionindogsacomparisonwithhumanmetabolicsyndrome
AT germanalexanderj obesityrelatedmetabolicdysfunctionindogsacomparisonwithhumanmetabolicsyndrome